What did @evanmxka actually say?
The creator is documenting a self-administered peptide protocol using BPC-157 and GHK-Cu, primarily targeting a lingering calf tear that has persisted for about three months despite ongoing physical therapy. He's working with a 10-day BPC-157 supply, injecting near the site of pain, and mixing both peptides into the same syringe. He also claims there are "easy amounts of studies" on both peptides, that negative side effects are minimal, and that taking zinc alongside GHK-Cu offsets copper load and reduces injection burn without interfering with benefits. He reported a three-hour burn on day one with GHK-Cu, some chin breakouts, and says the burn resolved by day two.
Does the science back this up?
Partially, but the creator is significantly overstating the human evidence. Most of the data is animal-based, and "easy amounts of studies" is a stretch. BPC-157 has shown promising tendon and soft tissue repair signals in rodent models, but human clinical trials are essentially nonexistent in peer-reviewed literature.
BPC-157, a synthetic peptide derived from a gastric protein, has shown regenerative effects on tendon, ligament, and muscle tissue in multiple rat studies (Sikiric et al., 2018, Current Pharmaceutical Design). The proposed mechanisms involve upregulation of growth hormone receptors and angiogenesis at injury sites. However, zero randomized controlled trials in humans exist for musculoskeletal injury repair. GHK-Cu has a longer research history, particularly for skin remodeling and wound healing. Pickart and Margolina (2018, Symmetry) reviewed its ability to stimulate collagen synthesis and antioxidant activity in human fibroblast studies, which is meaningful but not the same as clinical trial outcomes. The zinc-copper antagonism claim has physiological plausibility, but no published study has specifically tested zinc supplementation as a GHK-Cu burn-mitigation strategy.
What did they get wrong (or right)?
He got the injection site logic broadly right for BPC-157, but the safety confidence is overplayed, the syringe-mixing practice is undocumented, and the breakout framing is speculation.
- Right: Localized injection near pain site. Some animal and anecdotal evidence does support proximal injection for BPC-157 in musculoskeletal applications. This is the dominant community practice, though not clinically validated.
- Overplayed: "Very minimal chance of any negative side effects." Long-term human safety data for BPC-157 does not exist. Saying side effects are minimal for a compound with no completed Phase I/II human trials is a confidence level the science has not earned yet.
- Wrong: The breakout attribution. Calling chin acne "completely normal because it's like a new thing for your skin" is not how skin physiology works. GHK-Cu's pro-angiogenic and growth-factor activity could theoretically influence sebaceous function, but there is no documented evidence that initial GHK-Cu use causes purging the way retinoids do. This is speculation dressed as fact.
- Unverifiable: Mixing both peptides in the same syringe. No compatibility or stability data exists for co-administration of BPC-157 and GHK-Cu in the same syringe. This is not automatically dangerous, but calling it fine is a guess.
What should you actually know?
If you are considering peptides for injury recovery, the honest answer is that the human evidence is thin, regulatory status matters, and self-administration without clinical oversight carries real risks that enthusiasm cannot paper over.
BPC-157 and GHK-Cu are not FDA-approved for any indication. BPC-157 was placed on the FDA's list of substances that cannot be compounded for human use in 2023 in the United States, which has significant legal and sourcing implications. GHK-Cu exists in topical cosmetic products legally, but injectable formulations are a different regulatory category entirely. The source quality of peptides purchased outside a licensed telehealth provider is genuinely unknown. Bacterial endotoxin contamination, incorrect reconstitution, and dosing errors are all documented risks in the gray-market peptide space. Physical therapy three times a week, which the creator is already doing, has far more human evidence for calf strain recovery than any peptide currently does. That is not a dismissal of peptide research, it is just where the evidence sits right now.